$VTRS

Campbell Paul sold $810K of VTRS

Campbell Paul (See Remarks) sold 50,076 shares of Viatris Inc (VTRS) at $16.17 ($0.81M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Campbell Paul
Published Jun 26, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTRS
Neutral
medium confidence
Mentioned
$VTRS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTRSNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings; it can marginally influence sentiment but does not change fundamentals by itself.

02

Market read

A scheduled insider sale under 10b5-1 is typically low-signal; any trading impact is likely limited unless part of a broader pattern.

03

What to watch

Traders may over-weight single insider sales; without context on prior insider activity, net selling trend, or concurrent fundamentals, the signal is weak.

Relevance 4/10Novelty 5/10Timing: after-hours/filing time (Form 4 filed 2026-06-26)

Background

The article is an SEC Form 4 insider transaction disclosure for Viatris (VTRS).

Company-level read

Ticker impact

$VTRSNeutralMedium confidence
Context

Viatris insider Campbell Paul sold 50,076 shares at $16.1711 via an open-market transaction under a 10b5-1 plan, per Form 4 filed June 26.

Expected impact

Likely limited near-term price impact; any effect should be small and fade unless followed by additional insider selling or fundamental news.

Evidence & confidence

The filing is a primary-source Form 4, but it specifies a pre-arranged 10b5-1 plan and the article provides no accompanying fundamental catalyst.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than a change in outlook.

Key entities

  • Viatris Inc

    Subject of the Form 4 insider transaction disclosure.

  • Campbell Paul

    Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

$VTRSHighAI 9/10

Viatris to Acquire Pacira Biosciences for USD 1.65 Billion, Adds Exparel, Zilretta to Pain Portfolio

Viatris (VTRS) will acquire Pacira Biosciences (PCRX) for $1.65B, or $36.50 per share, a 44.8% premium. Pacira shares rose 44%, Viatris fell 2%. The deal adds Exparel and Zilretta to Viatris' pain portfolio, with 2025 sales of $575.1M and $116.6M. Viatris plans to fund the deal with cash and short-term borrowings, expecting minimal leverage impact and immediate accretion.

$VTRSHighAI 8/10

Viatris’ $36.50 Pacira Bid Looks Hard To Top

Viatris offered $36.50 per share to acquire Pacira, a 45% premium. Pacira's board supports the deal, and RBC raised its price target to the offer price. Pacira's stock traded near $36.31, indicating investor confidence in a swift closure.

$VTRSHighAI 9/10

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

Viatris (VTRS) agreed to acquire Pacira BioSciences (PCRX) for $1.65B in cash, or $36.50 per share. The deal expands VTRS's pain management portfolio, adding two marketed therapies and a gene therapy candidate. PCRX shares surged 44.4% post-announcement. The transaction is expected to close by the end of 2026 and is anticipated to be immediately accretive to VTRS's financial guidance. Pacira generated $746M in revenue and $177M in adjusted EBITDA in the 12 months ended June 30, 2026.

$VTRSHighAI 9/10

Viatris to Acquire Pacira in $1.65 Billion Deal

Viatris Inc. will acquire Pacira BioSciences Inc. for $1.65 billion, or $36.50 per share in cash. Pacira's products, EXPAREL and ZILRETTA, are expected to complement Viatris' portfolio and expand its reach in non-opioid pain management. Both companies' CEOs highlighted the strategic benefits of the deal, including accelerated growth and expanded patient access. According to Viatris, the acquisition advances its innovative medicines strategy and adds to its R&D capabilities.